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Background: Obesity is associated with the onset of type 2 diabetes mellitus (T2D), but reports conflict regarding the
association between obesity and macrovascular complications. In this study, we investigated associations between
cardiovascular risk factors and body mass index (BMI) and glycemic control in non–insulin-treated patients with T2D.
Methods: Authors gathered cross-sectional data from five observational studies performed in Spain. Generalized logit
models were used to analyze the relationship between cardiovascular risk factors (independent variables) and 5 BMI
strata (<25 kg/m2, 25 to <30 kg/m2, 30 to <35 kg/m2, 35 to <40 kg/m2, ≥40 kg/m2) and 5 glycated hemoglobin (HbA1c)
strata (≤6.5%, >6.5–7%, >7–8%, >8–9%, >9%) (dependent outcomes).
Results: In total, data from 6442 patients were analyzed. Patients generally had mean values of investigated
cardiovascular risk factors outside recommended thresholds. Younger patients had higher BMI, triglyceride levels
and HbA1c than their older counterparts. Diastolic blood pressure, systolic blood pressure and triglyceride levels
were directly correlated with BMI strata, whereas an inverse correlation was observed between BMI strata and
high-density lipoprotein cholesterol (HDL-C) levels, patient age, and duration of T2D. Increased duration of T2D
and total cholesterol levels, and decreased HDL-C levels were associated with a higher HbA1c category. BMI and
HbA1c levels were not associated with each other.
Conclusions: As insulin-naïve patients with T2D became more obese, cardiovascular risk factors became more
pronounced. Higher BMI was associated with younger age and shorter duration of T2D, consistent with the notion
that obesity at an early age may be key to the current T2D epidemic. Glycemic control was independent of BMI but
associated with abnormal lipid levels. Further efforts should be done to improve modifiable cardiovascular risk factors.
Keywords: Cardiovascular disease, Glycosylated hemoglobin A, Prevalence, Obesity, Observational research, Risk factorsBackground
Intricate, heterogeneous sociosanitary, and cultural cir-
cumstances are behind the past and projected steady in-
crease in the prevalence of type 2 diabetes mellitus
(T2D) [1]. The critical public health priority of diabetes
prevention does not imply control of this phenomenon
is straightforward. In the absence of effective pharma-
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unless otherwise stated.interventions should be based on weight control, physical
activity, and improved quality of diet. However, such inter-
ventions are difficult to implement at the population level
[3,4]. Consequently, health systems are increasingly con-
fronted with the task of improving diabetes surveillance
and management to reduce the long-term complications
of T2D [5]. Robust evidence supports the effectiveness of
appropriate glycemic control to prevent microvascular
complications in patients with T2D [6-8]. Conversely,
there is much less clarity regarding the potential of inten-
sive glycemic control to reduce macrovascular complica-
tions of T2D [9-11], although epidemiologic data andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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glycemic control and cardiovascular disease [12,13]. In
addition, macrovascular complications have consider-
able medical relevance because cardiovascular disease
is the leading cause of death in people with T2D [8,14].
Microvascular complications, such as persistent albu-
minuria, are also important contributors to cardiovas-
cular risk and may be driven by non-traditional risk
factors.
Obesity plays a central role in the pathophysiology of
both T2D and its macrovascular complications [1,15].
Nevertheless, some normal-weight individuals have
considerable risk of developing T2D and cardiovascu-
lar disease because they have a metabolically adverse
profile, including hyperinsulinemia, insulin resistance,
and hypertriglyceridemia [1,16]. Thus, a high body mass
index (BMI) is not necessary for the occurrence of
these conditions, suggesting that the underlying mech-
anisms of cardiovascular complications of T2D are not
straightforward.
Epidemiologic research of cardiovascular risk factors
among patients with T2D and different BMI ranges may
provide clues as to the relative contribution of obesity
to the cardiovascular risk of patients who already have
a higher risk of cardiovascular complications because
of T2D.
This article reports the results of an analysis of pooled
Spanish data from 5 observational studies of patients
with T2D during the last decade. The objectives were to
investigate the distribution of cardiovascular risk factors
among patients across a range of BMI strata, glycated




This report presents a post hoc analysis of cross-
sectional demographic and clinical data pooled from the
baseline assessments of observational studies of patients
with T2D. All patients evaluated in these studies pre-
sented within the normal course of care. Only data from
patients naïve to insulin therapy and recruited in Spain
were included in this analysis.
Description of source studies
The authors used data from 5 observational studies con-
ducted during the last decade in the primary or second-
ary (endocrinology or internal medicine) outpatient care
settings. One study was multinational, but the current
analysis only used data accrued at sites within Spain.
The remaining were nationwide studies performed in
Spain. The objectives and designs varied between the
studies, although all shared a focus on patients with T2D
in the preinsulin stage, diagnosed more than 1 year priorto study entry, and collected the same information
regarding classical cardiovascular risk factors. Briefly,
the studies were:
 Rodríguez et al. [17]: Prospective cohort study of
patients with T2D progressing from oral monotherapy
to combination therapy. The primary objective related
to evaluation of serum lipid profiles. There were 2470
eligible patients from this study.
 Rodríguez et al. [18]: Retrospective and cross-
sectional evaluation of patients with T2D naïve to
insulin therapy. The primary objective was to assess
the quality of healthcare. There were 2264 eligible
patients from this study.
 Rodríguez et al. [19]: Cross-sectional evaluation of
patients with T2D receiving any therapy. The primary
objective was to estimate the prevalence of the
metabolic syndrome according to several definitions.
Data were available from 1345 patients, but only data
from those patients who were not receiving insulin
therapy (n = 1066) were selected for this pooled
analysis.
 Dilla et al. [20]: Retrospective and cross-sectional
evaluation of patients with T2D receiving any therapy.
The primary objective was to evaluate the impact of
BMI on direct healthcare costs. Data were available
from 738 patients, but only data from those patients
not receiving insulin therapy (n = 488) were selected
for this pooled analysis.
 Costi et al. [21]: Prospective evaluation of patients
with T2D starting insulin therapy. The primary
objective was to estimate the direct health care
costs associated with the first 24 months of insulin
therapy. Five European countries participated in this
study. Only the baseline data from 178 patients
recruited in Spain were eligible for this analysis.
Of the 6466 patients eligible from the included studies,
a total of 6442 patients provided sufficient data and were
included in the analyses. All provided their informed
consent to release information in the respective study
they entered. The protocols were in compliance with the
Declaration of Helsinki and statutory requirements for
observational clinical studies in Spain and were approved
by accredited Ethics Committees.
Data management
The authors collated the following baseline patient data
from the source studies: age, sex, height, weight, smoking
status, waist circumference, time since T2D diagnosis, type
of therapy (lifestyle modifications alone or with oral anti-
diabetes drugs), HbA1c, fasting blood glucose (FBG),
total cholesterol (TC), low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C),
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stolic blood pressure (DBP). BMI was taken from studies
that provided this information and derived for the
remaining patients.
All patients with available data, including patients
with protocol violations, were included in the pooled
analyses. The rules to define spurious data were: TC
or triglycerides >2000 mg/dL, HDL-C >300 mg/dL, SBP/
DBP <50/< 30 mmHg, height <100 cm, BMI <10 kg/m2
or >100 kg/m2, time since T2D diagnosis >100 years,
FBG >1000 mg/dL, and HbA1c >50%.
Data analysis
The data were described as means, standard deviations
(SDs) and 95% confidence intervals, or absolute and
relative frequencies. Descriptions were stratified by sex,
age (<45 years, 45–64 years, 65–75 years, >75 years),
BMI (<25 kg/m2, 25 to <30 kg/m2, 30 to <35 kg/m2,
35 to <40 kg/m2, ≥40 kg/m2), and HbA1c ranges
(≤6.5%, >6.5–7%, >7–8%, >8–9%, >9%).
Two cumulative logit models were calculated to analyze
the relationship between cardiovascular risk factors
(independent variables: TC, LDL-C, HDL-C, triglycer-
ides, SBP, DBP, and current/previous tobacco use) and
the ordinal BMI and HbA1c strata described (dependent
outcomes). Dummy coding was used to calculate the
odds ratios, using the reference categories of <25 kg/m2
for BMI and ≤7% (combination of ≤6.5% and >6.5–7%
categories) for HbA1c. Both models were reduced using
stepwise variable selection at P < .05 in the model likeli-
hood ratio test.
The sample size for these analyses was not set a priori,
and only the available data from each study were used.
Results
Patient characteristics and variation with age
Table 1 describes the baseline characteristics of the 6442
patients analyzed (Additional file 1: Table S1 provides
these data for each study). Overall, slightly less than
one-half the patients were women, although this propor-
tion increased with increasing age. The mean (SD) age
of patients was 63.2 (10.9) years, and their anthropomet-
ric measures indicated that 46.5% were within the range
of obesity [overall mean (SD) BMI: 30.3 (5.2) kg/m2],
predominantly of the central type (mean waist circum-
ference, all: 101.8 cm; women: 99.5 cm, men: 103.7 cm).
The mean (SD) duration of T2D was 7.4 (6.7) years, and
more than 90% of patients were receiving oral antidia-
betes drugs; the remainder was receiving lifestyle change
advice only. Mean FBG and, particularly, mean HbA1c
were above classical non-individualized recommended
targets (mean FBG: 9.0 mmol/L; mean HbA1c: 7.4%).
Apart from HDL-C, SBP, and DBP, mean values of the
remaining classical cardiovascular risk factors (LDL-C andtriglycerides) were above their recommended thresholds.
These thresholds are summarized in Figure 1.
A greater proportion of men than women was in the
overweight range (BMI 25 to <30 kg/m2), while women
were more frequently in the obese range (BMI ≥30 kg/m2),
in particular BMI 35 to <40 kg/m2. Smoking was more
common among men than women (Table 1).
There was an inverse relationship between age group
and BMI, HbA1c, triglyceride, and DBP levels (Figure 1
stars: charts 2, 5, 8, and 10, respectively). Conversely, as
age increased, the duration of T2D also increased, as did
HDL-C and SBP levels (Figure 1 stars: charts 4, 6, and
9, respectively).
BMI and cardiovascular risk factors
Triglyceride, SBP, and DBP levels were directly corre-
lated with BMI strata (Figure 1 triangles: charts 8–10,
respectively). Conversely, as BMI increased, HDL-C
levels decreased (Figure 1 triangles: chart 6); LDL-C
levels did not show strong trends with BMI in either
direction (Figure 1 triangles: chart 7). The generalized
logit analysis confirmed positive associations between in-
creasing BMI strata and SBP, DBP, and triglyceride levels
as significant (P < .05 for all). It also indicated an inverse
association between increasing BMI strata and HDL-C
levels (P < .001) and a weaker inverse association between
increasing BMI strata and LDL-C levels (P < .05).
There was an inverse relationship between BMI strata
and both age and duration of T2D (Figure 1 triangles:
charts 1 and 4, respectively). The generalized logit analysis
confirmed these associations were significant (P < .001).
HbA1c did not appear to be correlated with BMI strata
(Figure 1 triangles: chart 5). The generalized logit analysis
also revealed that higher BMI strata was significantly asso-
ciated with female sex (P < .001).
HbA1c and cardiovascular risk factors
Increased values for the cardiovascular risk factors LDL-C,
triglycerides, SBP, and DBP, and decreased levels of HDL-C
were related to higher HbA1c strata (Figure 1 circles:
charts 7–10 and 6, respectively). In the generalized logit
analysis, lower HDL-C (P < .001) and higher TC levels
(P < .001) were associated with higher HbA1c strata. BMI
and waist circumference did not show an association with
HbA1c (Figure 1 circles: charts 2 and 3, respectively).
There was an inverse relationship between age and
HbA1c strata and a positive relationship between duration
of T2D and HbA1c strata (Figure 1 circles: charts 1 and 4,
respectively). In the generalized logit analysis, duration of
T2D was associated with higher HbA1c strata (P < .001).
Discussion
In this population of patients with T2D at the preinsulin
stage, most of the modifiable cardiovascular risk factors
Table 1 Characteristics of patients analyzed
All patients Mena Womena
Characteristic (N = 6442) (N = 3405) (N = 3036)
Sex: Female [n (%)] 3036 (47.1) — —
Current age (years) [mean (SD)] 63.2 (10.9) 62.2 (10.8) 64.3 (11.0)
< 45 [n (%)] 324 (5.0) 186 (5.5) 138 (4.6)
45–64 [n (%)] 3074 (47.7) 1756 (51.6) 1317 (43.4)
65–75 [n (%)] 2209 (34.3) 1082 (31.8) 1127 (37.1)
> 75 [n (%)] 824 (12.8) 374 (11.0) 450 (14.8)
BMI (kg/m2) [mean (SD)] 30.3 (5.2) 29.5 (4.4) 31.2 (5.9)
< 25 [n (%)] 769 (11.9) 431 (12.7) 338 (11.1)
25 to <30 [n (%)] 2672 (41.5) 1604 (47.1) 1068 (35.2)
30 to <35 [n (%)] 1979 (30.7) 1010 (29.7) 969 (31.9)
35 to <40 [n (%)] 711 (11.0) 279 (8.2) 431 (14.2)
≥ 40 [n (%)] 311 (4.8) 81 (2.4) 230 (7.6)
Current or previous smoker [n (%)] 2007 (31.2) 1720 (50.5) 287 (9.5)
Waist circumference (cm) [mean (SD)]b 101.8 (12.8) 103.7 (12.2) 99.5 (13.1)
Duration of diabetes (years) [mean (SD)] 7.4 (6.7) 7.0 (6.3) 7.8 (7.0)
Patients on oral antidiabetes drugs [n (%)] 6046 (93.9) 3173 (93.2) 2872 (94.6)
HbA1c (%) [mean (SD)] 7.4 (1.5) 7.3 (1.5) 7.4 (1.4)
≤ 6.5 [n (%)] 1911 (29.7) 1055 (31.0) 856 (28.2)
> 6.5–7 [n (%)] 939 (14.6) 490 (14.4) 449 (14.8)
> 7–8 [n (%)] 1664 (25.8) 870 (25.6) 794 (26.2)
> 8–9 [n (%)] 997 (15.5) 493 (14.5) 504 (16.6)
> 9 [n (%)] 767 (11.9) 406 (11.9) 360 (11.9)
FBG (mmol/L) [mean (SD)] 9.0 (2.9) 9.0 (2.9) 9.1 (2.9)
Total cholesterol (mmol/L) [mean (SD)] 5.2 (1.1) 5.1 (1.2) 5.3 (1.1)
HDL-C (mmol/L) [mean (SD)] 1.3 (0.4) 1.2 (0.4) 1.3 (0.4)
LDL-C (mmol/L) [mean (SD)] 3.2 (0.9) 3.1 (0.9) 3.2 (0.9)
Triglycerides (mmol/L) [mean (SD)] 1.9 (1.3) 1.9 (1.5) 1.8 (1.1)
SBP (mmHg) [mean (SD)] 139.1 (17.7) 138.0 (17.1) 140.4 (18.3)
DBP (mmHg) [mean (SD)] 79.7 (10.3) 79.5 (10.3) 80.0 (10.2)
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; HbA1c: glycosylated hemoglobin; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SD, standard deviation; T2D, type 2 diabetes.
aThe sex of 1 patient was not recorded.
bA total of 3709 patients provided data for this variable.
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goals (see Figure 1 for goals). As BMI strata increased,
we found that impairment of most cardiovascular risk
factors increased as well, and this was confirmed using
generalized logit analysis. Indeed, cardiovascular risk
factors were most prominent in patients in the higher
BMI strata. This finding is in agreement with that of
Gomis et al. [22], who reported an increased frequency
of dyslipidemia and hypertension with increasing BMI
among 7371 Spanish patients with T2D (P < .0001). By
contrast, although glycemic control (HbA1c strata) also
appeared to be associated with most of the cardiovascularrisk factors we considered, the association was significant
only for duration of T2D and dyslipidemia.
Noteworthy, BMI strata were also inversely related to
age and duration of T2D. This relationship between
BMI strata and age is consistent with previously pub-
lished data [23,24]. Previous epidemiological studies in
Spain, performed over the entire age spectrum of the
general adult population, had found a direct association
between BMI and age up to the fifth or sixth decade
[25,26]. Our patients, all of whom had T2D, had higher
BMI values on average than their Spanish population
peers [25,27,28]. The inverse association between BMI
Age (years)
55 57 59 61 63 65 67
T2D duration (years)
3 4 5 6 7 8 9 10
SBP (mm Hg) 
Target: < 140 mm Hg
127 133 139 145
DBP (mm Hg) 
Target: < 80 mm Hg
75 78 81 84
LDL (mmol/L) 
Target: <2.6 mmol/L
2.5 2.7 2.9 3.1 3.3 3.5
Waist circ. (cm)
85 94 103 112 121 130
BMI (kg/m2)
28 29 30 31 32 33 34
HbA1c (%) 
Target: <7%
6.8 7.0 7.2 7.4 7.6 7.8
HDL (mmol/L) 
Target males: <1.0 mmol/L 
Target females: <1.3 mmol/L 
1.0 1.1 1.2 1.3 1.4
Triglycerides (mmol/L) 
Target: <1.7 mmol/L 
1.0 1.5 2.0 2.5 3.0
1 2 3 4
5 6 7 8
9 10
<25 6.5
BMI (   )
(kg/m2)
HbA1c (   )
(%)
25 to <30 6.5 - 7
30 to <35 7 - 8
35 to <40 8 - 9
40 9
<45
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Figure 1 Classic cardiovascular risk factors and other patient characteristics stratified by age, BMI, and HbA1c ranges. Values are means
and 95% confidence intervals, calculated within the indicated strata of the dependent variables (age, BMI, and HbA1c). The vertical dotted lines
in some charts represent target values recommended by the American Diabetes Association [8]. Stars = age; Triangles = BMI; Circles = HbA1c.
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; T2D, type 2 diabetes.
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recognized role that obesity at early ages has in the
current T2D epidemic [29-31]. This role would entail a
reduction in the age of onset of T2D [29].
In addition, the most recent estimates of T2D preva-
lence in Spain were considerably high and included a
large proportion of undiagnosed cases, which were
younger and more obese than previously diagnosed
patients [32]. In consequence, in Spain, as in other coun-
tries [3], effective prevention and therapeutic strategies,
and T2D surveillance specific for overweight or obese
youth, are required. It has been shown that obesity in
early ages may not permanently increase cardiovascular
risk if it is treated successfully [33]. On the other hand,if left unchecked, sustained increases in obesity and T2D
prevalence might, in the mid-term, offset the declines in
cardiovascular mortality [34] and the positive influences
in longevity [35] achieved over recent decades in Western
countries.
Although the HbA1c target of below 7.0% was not
met by more than one-half the patients in this analysis,
70% of our sample had HbA1c below 8%. Notably, in pa-
tients older than 75 years of age, mean HbA1c was close
to 7.0%, whereas in all groups of younger patients it
was somewhat higher (Figure 1 stars: chart 5). Similarly,
Vinagre et al. [36] found that, in Catalonia, patients
with T2D aged ≥65 years were more likely to achieve
HbA1c ≤7.0% than younger patients. It is likely that the
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analysis were those with a more easily managed hypergly-
cemia. Glycemic control was related to T2D duration
in the current analysis, but this duration was similar in
patients aged >75 years and in those aged 65–75 years. A
more recent analysis of the Catalan data similarly re-
vealed deterioration in glycemic control with increasing
duration of T2D [24]. The major randomized clinical trials
that provided evidence supporting intensive glycemic con-
trol (ACCORD [37], ADVANCE [38], and VADT [39]) also
confirmed the importance of adequate, comprehensive
treatment of cardiovascular risk factors to prevent
macrovascular complications [10], and this aspect of
patient management was insufficiently addressed in the
patients of this pooled analysis. When compared with
results of a pooled analysis of population-based studies
of cardiovascular risk factors performed within the last
decade in Spain [40], our patients had similar cholesterol
levels, but mean BMI, SBP, and triglyceride levels were
higher. Of note, control of cardiovascular risk factors
seemed to be slightly better in the systematic evaluation
of patients with T2D recently performed in Catalonia,
even though about a quarter of those evaluated were
receiving insulin therapy and the Catalan population was
slightly older than patients in this analysis [36]. We
should highlight that the control of glycemia and cardio-
vascular risk factors might have improved in recent years,
because Vinagre et al. [36] gathered information as of
2009, while the present series spanned the last decade.
Our analyses did not show that BMI and waist circum-
ference were associated with HbA1c. This finding is not
unexpected, as some individuals with BMI in the obesity
range are otherwise metabolically healthy [41]. Indeed,
obesity does not seem to always be harmful, and there
are some phenotypes in which chronic metabolic inflam-
mation, probably a pivotal condition in obesity and dia-
betes, is not present. Investigations are therefore underway
to identify predictors or biomarkers of healthy versus un-
healthy obesity, such as heme oxygenase-1 [42], to allow
clinicians to better personalize treatment.
Patients included in our analyses were taking a variety
of medications for control of blood pressure and lipid
levels, and the blood pressure and lipid levels presented
in this manuscript are unadjusted for such medication
usage. Although this is consistent with the context of
summarizing cardiovascular risk factors in real life, it
limits our ability to assess 'underlying' blood pressure or
dyslipidemia in isolation.
Strengths of this research include a large sample size
and a variety of clinics. In addition, we only included
patients naïve to insulin therapy in our analyses to
reduce the confounding effect of insulin therapy on weight
[43] and cardiovascular risk factors such as hypertension
[44,45]. The limitations include the nature of this post-hocanalysis, performed with heterogeneous observational
studies, which were designed with different objectives.
As this was not a longitudinal analysis, cardiovascular
event rates could not be provided, we instead report a
description of cardiovascular risk factors across BMI
and HbA1c strata. Moreover, clinical data with known
therapeutic or prognostic implications, such as the pres-
ence and extent of retinopathy, persistent albuminuria,
or non-traditional cardiovascular risk factors/markers
were not captured. Regarding body composition, waist
circumference data were not available for about 40% of
the sample, and data were incomplete to evaluate the
‘healthy’ or ‘unhealthy’ metabolic condition of the obesity
seen in patients [46]. Finally, a significant percentage of
the patients in this analysis needed a progression in their
treatment for hyperglycemia, and this might have intro-
duced a bias towards the inclusion of those patients with
worse glycemic control.Conclusions
In summary, the results of this pooled analysis in insulin-
naïve patients with T2D show that glycemic control is
independent of BMI, but this is not the case for other
cardiovascular risk factors, such as hypertension and
hypertriglyceridemia. Greater effort should be under-
taken to reduce cardiovascular risk in patients with T2D,
particularly in young, obese individuals, by controlling
hypertension and dyslipidemia, as well as blood glucose.
Increased emphasis should also be given to treatment
strategies for weight control, especially in younger indi-
viduals and women.Additional file
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